Compare Johnson & Johnson (JNJ) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vale SA — how do they compare? Johnson & Johnson trades at $249.8 (market cap $598.96B), while Vale SA trades at $14.25 (market cap $59.07B). The key difference: Johnson & Johnson is far larger — about 10.1× Vale SA's market cap, and Vale SA pays the higher dividend (8.93%). Which is the better fit depends on your goals.
| JNJ | VALE | |
|---|---|---|
Market Cap | $598.96B | $59.07B |
Volume | 6,156,228 | — |
Sector | Health | Basic Materials |
52-Week High | $267.24 | $17.82 |
52-Week Low | $164.36 | $9.53 |
Enterprise Value | $631.90B | $75.99B |
Dividend Yield | 2.15% | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VALE trades at $14.08, down 0.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported $38.4B revenue for 2025 with net income of $2.35B, though earnings have missed expectations in two of the last three quarters. Recent news highlights governance challenges and a $2.6B decarbonization investment plan announced in June 2026.
While analyst consensus remains cautiously optimistic with a $17.63 price target, declining profit margins and recent earnings misses present headwinds. The stock offers value with reasonable P/E and EV/EBITDA multiples, but investors face risks from commodity price volatility and execution challenges in the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
